Dimerix Taps Everest for DMX-200 Asia License, Phase 3 Trial Enrolls 333 with >90% Power

For biotech investors, the deal with Everest Medicines represents a capital‑efficient move that provides non‑dilutive funding while validating DMX‑200’s clinical promise. With ACTION3 fully enrolled and a >90% chance of meeting its primary endpoint, the asset is significantly de‑risked, and Everest’s commercial reach in Asia offers a clear pathway to market.

On June 16, 2026, Dimerix Limited (ASX: DXB) announced an exclusive licensing deal with Everest Medicines, granting the latter rights to commercialize Dimerix's Phase 3 candidate DMX-200 in Greater China, South Korea, and select Southeast Asian countries. This press release, sourced from Dimerix, outlines a strategic regional partnership that covers all indications including Focal Segmental Glomerulosclerosis (FSGS), a rare and serious kidney disease with significant unmet need. DMX-200, a small-molecule inhibitor of the chemokine receptor 2 (CCR2), is currently in the pivotal ACTION3 trial, which has fully enrolled 333 adult patients, including participants from the licensed territories. The agreement allows Dimerix to retain all rights outside the licensed regions, preserving its ability to capture value in major Western markets.

“

With ACTION3 fully enrolled and a >90% chance of meeting its primary endpoint, the asset is significantly de‑risked, and Everest’s commercial reach in Asia offers a clear pathway to market.

FSGS is a kidney disease affecting roughly 210,000 patients globally, with a particularly high prevalence in Asia. The disease often leads to end-stage renal disease, requiring dialysis or transplant, and current therapies are limited to supportive care and off-label immunosuppressants with variable efficacy. DMX-200 represents a novel targeted approach: by inhibiting CCR2, it aims to reduce proteinuria, a key marker of kidney damage. The interim results reported in early 2024 showed DMX-200 outperforming placebo in reducing proteinuria, and after eight independent data monitoring committee reviews—most recently in June 2026—no safety concerns have emerged. In April 2026, an external blinded statistical review confirmed that the study retains over 90% statistical power to demonstrate a treatment effect on the primary endpoint of proteinuria, indicating a high probability of trial success if the drug's efficacy holds.

The partnership with Everest Medicines is a significant de-risking move for Dimerix. Everest brings deep expertise in rare renal diseases and a commercial infrastructure across Greater China, South Korea, and Southeast Asia—a region covering more than 1.7 billion people. While financial terms were not disclosed, such licensing deals typically include an upfront payment, development and regulatory milestones, and tiered royalties on future sales. This non-dilutive funding strengthens Dimerix's balance sheet as it advances toward the ACTION3 readout, expected in 2027–2028 based on the trial's current trajectory. For Everest, DMX-200 adds a late-stage asset with strong data to its portfolio, complementing its existing nephrology focus.

Industry observers note that the FSGS competitive landscape remains thin, with few targeted therapies in pivotal studies. The CCR2 mechanism has drawn attention, and positive Phase 3 results could position DMX-200 as a first-in-class treatment. Dimerix's decision to retain rights in the U.S., Europe, and other markets suggests it may pursue further partnerships or even independent commercialization in those regions, depending on the final data. The statistical power analysis, reported just two months before the licensing deal, likely bolstered Everest's confidence and may have influenced deal terms.

The announcement comes amid a growing wave of Asia-focused licensing deals for rare disease drugs, where population genetics create larger patient pools and regulatory pathways are gradually harmonizing. Greater China's National Medical Products Administration has accelerated approvals for novel drugs addressing serious unmet needs, and similar trends are seen in South Korea. Southeast Asia, while a smaller pharmaceutical market, presents a long-term opportunity as healthcare spending rises. Everest's footprint across these territories positions it well to execute on market access and reimbursement negotiations.